Helus Pharma CEO to Present at Guggenheim Healthcare Innovation Conference

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The session will be webcast live, with registration available through the conference webcast platform, and a replay will be posted on the Events & Presentations page of the company’s investor relations website.

The appearance matters because Helus Pharma is developing a pipeline of proprietary NSAs, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These candidates are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company’s lead program, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. A second candidate, HLP004, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.

Investor attention on the Guggenheim conference is likely to focus on the company’s clinical progress and the commercial potential of its NSA platform. Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom and Ireland. Company updates and additional information are available through www.helus.com.

The full press release can be viewed through this link. The announcement was disseminated on behalf of Helus Pharma and may include paid advertising.

The distribution was handled by InvestorWire, a communications platform focused on wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to more than 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available at https://www.InvestorWire.com/Disclaimer.

Blockchain verification QR code
Blockchain Registered
This article is registered on the blockchain by Newsramp. Verify this record.